<DOC>
	<DOCNO>NCT00192413</DOCNO>
	<brief_summary>To demonstrate efficacy defined surveillance period culture-confirmed influenza-illness cause community-acquired subtypes antigenically similar contain vaccine , adult age least 60 year enrollment , single intranasally ( IN ) -administered dose liquid formulation influenza virus vaccine , ( CAIV-T ) non inferior compare single dose commercially available influenza vaccine inactivate ( TIV ) administer intramuscularly ( IM ) prior anticipate commencement influenza season .</brief_summary>
	<brief_title>Trial Compare Safety , Tolerability , Efficacy Influenza Virus Vaccine , ( CAIV-T ) With Inactivated , Influenza Vaccine , Trivalent , Types A &amp; B , Adults Aged 60 Years Older Against Culture-confirmed Influenza</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>age least 60 year old time enrollment ; determine medical history , physical examination clinical judgement eligible study ; provide write informed consent nature study explain ; available duration trial ( enrollment November 30th , 2003 ) ; reach study staff postvaccination weekly surveillance contact [ telephone , clinic home visit ] . perceive unavailable difficult contact evaluation study visit study period ; resident nursing home longterm care facility institution receive skilled semiskilled nursing care ( refer Influenza study specific manual ) . An ambulatory subject resident retirement home village eligible trial ; sign renal insufficiency require supportive therapy progressive neurological disease . ( Subjects stable preexist disease , define disease require change therapy hospitalization within 12 week receipt study vaccination eligible ) . evidence dementia severe cognitive impairment base Mini Mental State Examination ( MMSE ) score ( refer Influenza study specific manual ) ; know suspected disease immune system receive immunosuppressive therapy , include systemic corticosteroid ; cytotoxic agent ; receive blood product , include immunoglobulin , period six month prior vaccination conclusion study ; immunosuppressed immunocompromised individual living household ; document history hypersensitivity egg egg protein component CAIVT TIV vaccine ; administer live virus vaccine within one month prior vaccination expect receive another live virus vaccine within one month vaccination study ; intent administer investigational vaccine agent one month prior enrollment conclusion study ; receive dose influenza treatment ( commercial investigational ) one month prior enrollment . The prophylactic use influenza antiviral permit . receive influenza vaccine 6 month prior enrollment , intend receive nonstudy influenza vaccine enrollment ; medical condition opinion investigator might interfere interpretation study result ; Note : A pregnant household member consider contraindication enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>